买赛车

澳利達集團簡介
2012-01-04 13:59:34   來源:   評論:0 點擊:

澳利達(ALD)醫藥集團簡介 澳利達醫藥集團創建于1985年,現已發展成為集科研能力、生產能力、營銷能力于一體的大型醫藥企業集團,擁有成員企業28家,資產13億元人民幣,員工2180人,年實現銷售收入13....
 澳利達(ALD)醫藥集團簡介

    澳利達醫藥集團創建于1985年,現已發展成為集科研能力、生產能力、營銷能力于一體的大型醫藥企業集團,擁有成員企業28家,資產13億元人民幣,員工2180人,年實現銷售收入13.5億元人民幣,利稅9500萬元人民幣。2000年全國流通百強企業排名第十七位,各項主要經營指標均居全國同行業領先地位。企業榮獲全國五一勞動獎狀、黑龍江省文明標兵、黑龍江省高新技術企業等殊榮,被黑龍江省人民政府確定為北藥開發重點培植企業。董事長周有財先生擁有藥學博士學位、北京大學EMBA學位,享受國務院特殊津貼,曾先后獲得國家科研基金、專利成果10余項,榮獲全國勞動模范、全國五一勞動獎章榮譽稱號,九屆、十屆、十一屆全國人大代表,黑龍江省工商聯副主席。
    澳利達奈德制藥有限公司(ALD NED)為集團的核心生產企業。公司由德國保爾工程公司和中國天辰化學公司按照國際標準進行設計,廠區三面農田環繞,空氣清新,無污染源,占地面積10萬平方米,建筑面積3.5萬平方米,內部規劃新穎獨特,結構科學合理,是目前亞洲地區規模較大、標準較高的新型制藥企業。公司現有軟膠囊劑、緩釋微丸劑、凍干粉針劑、水針劑、顆粒劑、片劑、硬膠囊劑、丸劑和口服液劑及化學合成車間。正在籌建噴霧劑、軟膏劑和發酵合成車間。發酵合成車間主要以發酵法生產L-谷氨酰胺,用于施林(復方L-谷氨酰胺)的生產,以上二個劑型和一個車間的工藝布局已在設計中。公司主要有奧邁必利緩釋微丸、奧地邁爾緩釋微丸、施林、奧力保克、考夫克、牛黃清感膠囊等近百個產品,獲得國家發明專利和國內獨家生產的品種9個。緩釋微丸技術已成為公司的主導技術,該技術具有給藥次數少,毒副作用小,保持平穩而有效血藥濃度的優勢,克服了普通藥物普遍存在的峰谷現象,最大限度的發揮了療效。以此技術生產研制的系列緩釋微丸產品均為國內首創,屬填補國內空白品種。公司年生產軟膠囊5億粒、緩釋微丸膠囊3億粒、凍干粉針2億支、水針1.5億支、顆粒劑10億袋、片劑10億片、硬膠囊10億粒。公司生產、檢驗設備先進,其中,FL-120沸騰干燥制粒機、DPH-200包裝聯動生產線等主要生產設備均達到國際先進水平。
    澳利達哈爾濱藥物研究所承擔著集團的藥品研發工作。科研力量雄厚,研發人員中現有博士學位7人,碩士學位12人,主任藥師7人。檢驗設備精密、先進。幾年來,相繼開發上市了復方谷氨酰胺顆粒、奧邁必利緩釋微丸、牛黃清感膠囊等近30多個品種。其中別嘌醇緩釋微丸獲得黑龍江省科技進步一等獎,復方谷氨酰胺顆粒獲得黑龍江省醫藥行業協會科技進步一等獎,牛黃清感膠囊獲得國家藥物組方發明專利。緩釋微丸項目被國家發改委列為高新技術產業發展專項。近年來,藥物研究所的主要研究方向一是中藥現代化的研究,二是開發緩釋微丸技術,三是五味子產業化的研究,并均取得了理想的經濟效益和社會效益。
    澳利達藥業股份有限公司作為集團的核心企業之一,承擔著集團產品的營銷工作,公司在北京和上海設有兩個事業部,在沈陽、天津、成都、重慶、廣州、西安等21個大中城市設有銷售服務機構,業務網點遍及國內31個省、區、市,與此同時與日本第一制藥、法國愛的發制藥建立了長期穩固的業務關系。
    集團控股公司天一藥房與美信醫藥國際連鎖機構聯合,引用國際醫藥管理技術及理念,建立輻射全國的醫藥連鎖網絡,推進整合行銷和多品牌營銷等全新營銷模式,經營“健康+專業+便利”理念的藥房,預計2011年國內連鎖門店總量達到1000家,為顧客提供個性化照顧和高品質服務,締造最優秀的專業藥房。構建營銷網、物流網、信息網有機整合的國內醫藥零售連鎖網絡體系。
    集團藥品物流中心和生物制藥與生物保健品生產基地位于哈爾濱市機場路,占地30000平方米,投資1.5億元。物流中心負責集團生產和經營藥品的全國配送業務,生物基地主要生產生物信息素、生物保健品。面向未來,集團恪守“精制良藥,造福人群”的經營理念,立足國內,放眼世界,以科學嚴謹、追求創新的態度和精神,使集團發展成為具有競爭力和蓬勃發展的國際化集團企業。
 
Introduction to Heilongjiang Aolida Medical Group
 
The Heilongjiang Aolida Medical Group (“ALD Group”), founded in 1985, has expended into a multi-industrial company through the past 23 years. It is now a leading pharmaceutical enterprise operating product developing, manufacturing and marketing in diversified pharmaceutical products. ALD Group possesses a total capital of 1.3 billion RMB inclusive of 28 subsidiaries. With more than 2,180 employees’ diligent work, ALD Group successfully realized a business income of 1.35 billion RMB and tax revenue of 95 million RMB last year.
 
ALD Group ranked 17th of the top 100 state circulation enterprises in 2000 and it now also leads the pharmaceutical industry of varied major indices. ALD Group has won many national and province wide awards such as National Labor Award and Cultural Pivot of Heilongjiang Provence. It is also recognized as High-New Technology Enterprise of Heilongjiang. ALD Group has been determined as the key cultivation enterprise of the North medicine development by the government of Heilongjiang Province.
 
Mr. Zhou Youcai, the chairman of ALD Group, is a PhD in pharmaceutics and also holds EMBA degree from Peking University. Mr. Zhou enjoys the special allowance from the national council and has obtained the national scientific research fund and more than 10 patent achievements, he had the honor to receive the national labor model, and the ninth, tenth, eleventh NPC, and he is the vice chairman of federations of industry in Heilongjiang province.
 
Heilongjiang Aolida Ned Pharmaceutical Co. Ltd. (“ALD NED”) is the core production of ALD Group. The company carries on the design by the German Paul Engineering and the Chinese Tian Chen chemistry company according to the international standard. The factory of ALD NED covers 100,000 square meters with 35,000 square meters floor space and is surrounded by farmland on three sides. It has a modern interior design with unique and sound layout. ALD NED is a pharmaceutical enterprise with large scale and high standard in Asian area.
 
 ALD NED has nine cGMP facilities, mainly manufacturing nine formulations: soft capsules, slow-release nano-pills (sustained-release pellets), freeze-dry powder syringes, liquid syringes, particles, tablets, hard capsules, pills, and oral liquid. The workshop for spray solution, soft medicinal extract and fermentation synthesizes is being prepared to construct. Fermentation synthetic workshop is to synthesize L – glutamine which is produced mainly by fermentation. L-Glutamine is a necessary to produce Shilin. The layout of above mentioned workshop is being designed.
 
By now, ADL Group has Aomaibili sustained-release pellets, Aodimaer sustained-release pellets, Shilin, Aolibaoke, Kaofuke, Niuhuang Flu Pills, nearly hundred kinds of products. Among those products, nine of them obtained the patent of Chinese invention and exclusive production rights in China. The technology of sustained-release pellets has already been the leading technology within the company. The advantage of the sustained-release pellets is that it need less dosing, has fewer side effects and could maintain the drug concentration smoothly and effectively. The sustained-release pellet has overcome the volatility in ordinary medicine to reduce the stimulation of gastro-intestinal tract. It is a cutting-edge technology first appears and fills the gap of sustained-release pellet in China.
 
ADL Group is capable to produce a total of 500 million of capsules, 300 million of slow-release nano-pills, 200 million of freeze-dry powder syringes, 150 million bottles of liquid syringes, 1 billion bags of particles, 1 billion of pills and 1.5 billion bottles of oral liquid in each year. It has the advanced production line and examination facilities. The major production line such as FL-120 ebullition dry pelletizer and the DPH-200 packing production lines have reached the advanced international level.
 
Harbin Aolida pharmaceutical institute is undertaking the research and development work of ALD Group. It has strong capability of conducting scientific research. The research team includes 7 doctors, 12 masters and 7 professors of pharmacy. The institute also has advanced examination facilities such as liquid phase chromatograph, gas phase chromatograph, infrared spectrophotometer and visual purple spectrophotometer which are all introduced from overseas.
 
ALD Group has developed L – glutamine, Aomaibili sustained-release pellets and Niuhuang Flu Pills nearly 30 kinds of production in the past several years. The Aomaibili sustained-release pellets has won the first prize of the advance technology in Heilongjiang Province, L – glutamine has won the first prize of medicine profession association advance technology in Heilongjiang province and Niuhuang Flu Pills has won the patent of national medicine group of invention. The project of slow-release nano-pills is recognized as the special project of new and high technology by national Development and Planning Commission.
 
In recent years, Aolida Pharmaceutical institute has focused research on three major areas: 1. modernization of traditional Chinese medicine; 2. development of the technology of slow-release nano-pills; 3. the sub-industrial production research of the fruit of Chinese magnolia vine. The results of research returned ALD Group favorable economic efficiency and the social efficiency.
 
As the one of the Core enterprises, Aolida pharmaceutical industry Limited liability company which undertakes the marketing activities of ALD Group. The company has two sales divisions located in Beijing and Shanghai and also operates sales departments within 21 cities, such as Shenyang, Tianjin, Chengdu, Chongqing, Guangzhou, Xi'an etc. It services 31 provinces and cities. At the same time pharmaceutical limited has established a long-term stable business relation with the first drugs manufacture of Japan and Ethypharm of France.
 
ALD Group introduces the advanced management and company principles by alliance of controlled subsidiary Tianyi pharmacy and Meixin international chain store. It established the sales network which radiates to the whole country. By integrated its marketing and set multi-brand strategy, ALD Group promotes a new marketing model which advocates “health + professional + convenience”. As a result of building sales and logistic network and providing finest service in addition to specialized pharmacy, number of the chain stores is estimated to reach 1,000 by year 2011.
 
The logistic center sits together with biopharmaceutical and health care product manufacturing base in Haerbin Airport Road. It total investment is 150 million RMB and covers a total of 30,000 square meters. The logistic center is responsible to distribute all drugs produced and operated by ALD Group to the whole country. The manufacturing base is to produce the biology information element, and the biological healthy product.
 
Aiming to the future, ALD Group will follow the enterprise spirit of “Improves the medicine quality unceasingly, and benefits the humanity”. With the attitude towards preciseness and spirit of pursuing innovation, ALD Group is developing its competitiveness and striving not only to be the top in pharmaceutical industry in China but also to take a part in the global market.
 
 

相關熱詞搜索:澳利達 澳立達 集團

上一篇:第一頁
下一篇:企業榮譽

分享到: 收藏
頻道本月排行
买赛车 中彩网开奖结果排列五 三分赛车彩票骗局 小猫变身水果机下载 内蒙古时时11选5结果 248彩票APP 竞彩半全场稳赚技巧 时时开奖结果直播 陕西11选5前三组预测号 体彩p5今日开奖结果走势图 体彩大乐透开奖结果19068